

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 2, 2012

OPKO Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33528

75-2402409

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

4400 Biscayne Blvd., Miami, Florida

33137

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Item 1.01 Entry Into a Material Definitive Agreement.

On August 2, 2012 (the “Closing Date”), OPKO Health, Inc., a Delaware corporation (the “Company”), and Shebeli XXI, S.L.U., a company organized under the laws of Spain and a wholly-owned subsidiary of the Company (“Buyer”), entered into a stock purchase agreement (the “Purchase Agreement”) pursuant to which Buyer acquired Farmadiet Group Holding, S.L., a Spanish company engaged in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products in Europe (“Farmadiet”). Pursuant to the Purchase Agreement by and among the Company, Buyer, Farmadiet, José Junca Busquets (“JJB”), Miguel Juncá Riuró (“MJR”), Ferrán Juncá Riuró (“FJR”), Carlos Fernández Navarro (“CFN”), Catorze d’Agost, S.L., a Spanish company (“Catorze”), Agut Global, S.L., a Spanish company (“Agut Global”), and Colibrí 2000, S.L., a Spanish company (“Colibrí”, and together with JJB, MJR, FJR, CFN, Catorze and Agut Global, the “Sellers”), Buyer purchased from the Sellers all of the issued and outstanding shares of the capital stock of Farmadiet (the “Transaction”).

In connection with the Transaction, Buyer agreed to pay an aggregate purchase price of €13.5 million (US \$16.8 million), of which (i) €6.75 million (US \$8.4 million) was paid in cash at closing, and (ii) €6.75 million (US\$ 8.4 million) (the “Deferred Payment”) will be paid to the Sellers, at the Company’s option, in cash or shares of the Company’s common stock, par value \$0.01 (the “Common Stock”) as follows: (x) €3.376 million (US\$4.2 million) to be paid on the first anniversary of the Closing Date; and (y) €3.376 million (US\$4.2 million) to be paid 18 months after the Closing Date. In the event the Company elects to pay the Deferred Payment in shares of Common Stock, the number of shares issuable shall be calculated using the average closing sales price per share of the Company’s Common Stock as reported on the New York Stock Exchange for the ten trading days immediately preceding the applicable payment date. The Company has the right to hold back up to €2.8 million (US\$3.5 million) from the Deferred Payment to satisfy indemnity claims.

The stock consideration which may be issued in connection with the Deferred Payment will be issued in reliance upon an exemption from the registration requirements under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S or Section 4(2) thereof.

In connection with the Transaction, the Buyer also entered into two ancillary transactions (the “Ancillary Transactions”). In exchange for a forty percent interest held by one of the Sellers in one of Farmadiet’s subsidiaries, the Company agreed to issue up to an aggregate of 250,000 shares of the Company’s Common Stock, of which (a) 125,000 shares were issued on the Closing Date, and (b) 125,000 will be issued upon achieving certain milestones. In addition, the Company acquired an interest held by an affiliate of a Seller in a product in development in exchange for which the Company agreed to pay up to an aggregate of €1.0 million (US \$1.3 million) payable at the Company’s option in cash or shares of the Company’s Common Stock, of which (a) €0.25 million (US\$0.3 million) was paid at Closing through delivery of 70,421 shares of the Company’s Common Stock, and (b) €0.75 million (US\$1.0 million) will be paid in cash or shares of Common Stock upon achieving certain milestones. The number of shares of the Company’s Common Stock issued is determined based on the average closing sale price for the Company’s Common Stock on the NYSE for the ten (10) trading days preceding the required payment date.

The stock consideration issued or that may be issued in connection with the Ancillary Transactions was or will be issued in reliance upon an exemption from the registration requirements under the Securities Act, pursuant to Regulation S or Section 4(2) thereof.

## Item 2.01 Completion of Acquisition or Disposition of Assets.

The information disclosed under Item 1.01 of this report is incorporated into this Item 2.01 in its entirety.

## Item 3.02 Unregistered Sales of Equity Securities.

The information disclosed under Item 1.01 of this report is incorporated into this Item 3.02 in its entirety.

## Item 7.01 Regulation FD Disclosure.

On August 3, 2012, the Company issued a press release announcing that it entered into the Purchase Agreement. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Exchange Act.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company, dated August 3, 2012.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

*August 3, 2012*

*By: Adam Logal*

---

*Name: Adam Logal*

*Title: Vice President-Finance, Chief Accounting Officer,  
and Treasurer*

---

Exhibit Index

Exhibit No.	Description
99.1	Press Release of the Company, dated August 3, 2012



## **OPKO Health Announces Acquisition of Growing European Healthcare Company**

MIAMI, August 3, 2012— OPKO Health, Inc. (NYSE: OPK) today announced its acquisition of Farmadiet Group Holding, S.L., a Barcelona-based company currently engaged in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products.

With this acquisition, OPKO establishes a presence in the European Union through an established regional, integrated specialty pharmaceutical participant. This acquisition also allows OPKO near term product commercialization synergies through introduction of Farmadiet's products to OPKO's existing Latin American operations. Farmadiet's robust product development pipeline also offers many near-term new product entry opportunities.

Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer, commented, "This acquisition is an excellent strategic fit as we expand our global manufacturing, sales and distribution capabilities for a growing range of products. More specifically, through this acquisition, we further invigorate our strategic aim of broadening our footprint within the expanding worldwide pharmaceutical market while capitalizing on important commercial synergies across our existing operating base. We anticipate important launches near-term of products from Farmadiet's rich pipeline. We also expect Farmadiet to market OPKO's diagnostics and pharmaceutical products as they become available for market and sale. Finally, we are extremely pleased to benefit from Farmadiet's experienced, highly successful, management team and their many years of product development and commercial expertise," said Dr. Frost.

Further details of the agreement will be included in OPKO's 8-K filing with the Securities and Exchange Commission.

### **About OPKO Health, Inc.**

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

*This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our near term product commercialization synergies, our ability to sell Farmadiet's products through our existing Latin American operations, expectations regarding near-term new product entry opportunities, the expansion of our global manufacturing, sales and distribution capabilities, our ability to capitalize on important commercial synergies across our existing operating base, Farmadiet's ability to develop new and important products from its pipeline and our ability to launch any such products in the near term, whether Farmadiet will be able to successfully market any of OPKO's diagnostic and pharmaceutical products as they become available for market and sale and our ability to retain and benefit from Farmadiet's existing management team, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, integration issues with Farmadiet, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.*

### **Contacts:**

Steven D. Rubin 305-575-4100  
Juan F. Rodriguez 305-575-4100